Antibody Engineering Xchange West Coast 2018

Antibody Engineering

Titles and Bullets
9:00am – 10:00am

How to identify the best antibody discovery platforms to move forward with for lead identification
  • Which platforms are you using for active discovery projects?
  • What are the main strengths and weaknesses of these platforms?
  • What are the primary factors that influence your platform choices? (scientific, operational, IP/technology access)
  • Does/should desired antibody function (e.g. receptor agonism, ligand blocking) influence discovery platform choice?
  • Are you evaluating (or planning to evaluate) any new platform technology? What and why?

Vice President Preclinical

10:30am – 11:30am

Maximizing target-specific antibody sequence diversity in discovery campaigns
  • Considerations for immunization strategies (species, strains, and routes)
  • Perceived advantages and disadvantages of discovery platforms
  • Screening assay formats: Binders and functioners.

ImmunoPrecise Antibodies

12:00pm – 1:00pm

How to identify the best agonistic antibody for trimeric receptors such as TNF receptors for immuno-oncology
  • What are the considerations in selecting an agonistic antibody against TNFR?
  • What is the best format for agonistic antibodies targeting a TNFR, bivalent or trivalent?
  • Do you prefer partial, full, or super agonistic antibodies?
  • Is crosslinking two TNFRs or super-agonistic antibody preferred?
  • What kind of functional cell-based assays are predictable for in vivo efficacy?
  • What in vivo models can predict efficacy in clinic trials?

Senior Vice President
Head of Biologics Research

3:20pm – 4:20pm

Selection of antibodies specific for multi-pass membrane proteins using mammalian virus display
  • What are the biggest challenges to overcome to enable selection of antibodies specific for multi-pass membrane proteins?
  • What are the available technical solutions to these challenges?
  • How can recombinant virus display and VLPs be used to overcome these challenges?

Ernest Smith
Senior Vice President Research &
Chief Scientific Officer

4:20pm – 5:20pm

Interrogating the human immune system for antibody discovery.
  • What’s the best tissue source (blood, tumor, lymphoid tissue) to interrogate humoral response to cancer?
  • Should interrogation of humoral system be target-driven, target-agnostic or both?
  • Should screening assays focus on discovery of a single therapeutic antibody or a combination of multiple antibodies?
  • What are current challenges in screening assays to identify therapeutic antibodies?
  • What approaches are best suited to identify target for novel antibodies?

Vice President R&D


Antibody Engineering Xchange | West Coast 2018